间充质干细胞治疗强直性脊柱炎的临床疗效

目的:分析探讨间充质干细胞对强直性脊柱炎(AS)患者的临床治疗效果.方法:对2016年5月至2017年5月收治的82例AS患者进行回顾性研究,其中42例患者采用间充质干细胞进行治疗为观察组,40例患者采用抗风湿药物治疗为对照组,分析两组患者治疗前后血常规变化、肝功能水平变化、血沉指数、夜间疼痛VAS评分、Bath强直性脊柱炎功能指数(BASFI)评分和Bath强直性脊柱炎疾病活动性指数(BASDAI)评分变化.结果:经治疗后,观察组患者血常规红细胞计数(RBC)、白细胞计数(WBC)、血小板计数(PLT)、血红蛋白(HB)分别为(3.20±0.24)×1012/L]、(893.65±121.85)×109/L]、(192.64±7.68)×109/L]、(106.84±12.35)g/L],与治疗前相比差异具有统计学意义(t=9.40,30.14,7.08,5.34;P<0.05),且治疗后显著优于对照组(P<0.05);观察组患者谷丙转氨酶(ALT)、谷草转氨酶(AST)以及总胆红素(TBIL)水平分别为(17.24±4.96)U/L]、(28.03±4.96)U/L]、(10.07±1.42)μmoL/L],与治疗前相比差异显著(t=3.44,3.74,3.02;P<0.05);观察组患者治疗后VAS评分、BASFI评分以及BASDAI评分均显著优于治疗前(P<0.05),与对照组相比差异也具有统计学意义(P<0.05).结论:AS患者采用间充质干细胞治疗可以有效的改善患者的血常规和肝功能水平,且可以有效的缓解患者的临床症状,改善脊柱功能,效果显著,值得临床推广.

Clinical Effect of Mesenchymal Stem Cells on Ankylosing Spondylitis

Objective:To evaluate the clinical efficacy of mesenchymal stem cells in patients with anky-losing spondylitis ( AS) . Methods:A retrospective study was conducted on 82 patients with AS from May 20 to May 2017. Among them, 42 patients were treated with mesenchymal stem cells as observation group and 40 patients treated with anti-rheumatic drugs as control group ( BASF) score and the brachial ankylosis disease activity index ( BASDAI) score were measured before and after treatment, and the changes of liver function, blood pressure index, nighttime pain VAS score, Bath ankylosing spondylitis function index ( BASFI) score and Bath ankylosing spondylitis disease activity index Variety. Results:After treatment, the blood transfusion count ( RBC) , white blood cell count ( WBC) , platelet count ( PLT) and hemoglobin ( HB) were observed in (3.20 ± 0.24) × 1012/L], (893.65 ± 121.85 (106.84±7.68) ×109/ L],(106.84 ± 12.35) g / L], which was significantly different from that before treatment ( t = 9.40,30.14,7.08,5.34;P <( AST) and total bilirubin (TBIL) were significantly higher than those in the control group (P <0.05) (T = 3.44, 3.44, 3. 02;P <0.05) . The patients in the observation group were significantly higher than those in the control group ( P <0.05) After treatment, VAS score, BASFI score and BASDAI score were significantly better than before treatment ( P <0.05) , compared with the control group was also statistically significant ( P <0.05) . Conclu-sion:AS patients with mesenchymal stem cell therapy can effectively improve the patient ' s blood and liver function levels, and can effectively alleviate the clinical symptoms of patients, improve spinal function, the effect is remarkable, worthy of clinical promotion.